1. ALLA AKTIER
  2. NYHETER
  3. NEOLA MEDICAL

Neola Medical

Nyheter Neola Medical Nyheter alla bolag

Neola Medical’s CEO highlights recent steps toward market approval in the Autumn 2024 Investor Letter

Neola Medical AB takes significant steps toward securing market approval in the USA for continuous lung monitoring device, Neola®. These accomplishments include the company’s transition from technical verification phase to clinical validation phase, preparing for clinical studies on preterm born babies. Building on the progress to clinical validation, recent patent grants in both the USA and Europe, are strengthening the company’s competitive position and reinforces the protection of its innovation pipeline of medical device for continuous lung monitoring.

“We are making significant strategic advancements toward securing market approval in the USA for our continuous lung monitoring device, Neola®. We are not only advancing our commercialization strategy in the USA but also progressing to clinical validation, preparing a pivotal clinical study in the USA, which will be instrumental in supporting Neola Medical's forthcoming FDA application and bringing our medical device for continuous lung monitoring, Neola® to market.”, says CEO Hanna Sjöström.

Read more about the latest news in the investor letter autumn 2024, attached to this press release and available on the company’s website www.neolamedical.com

For further information, contact:
Hanna Sjöström, CEO
e-mail: hanna.sjostrom@neolamedical.com

About Neola Medical
Neola Medical AB (publ) develops revolutionizing medical technology device for non-invasive continuous lung monitoring and real-time alerts of life-threatening lung complications of preterm born infants. Immediate detection of complications provides the possibility of early treatment, improved health care and healthier lives for preterm born infants. The patented cutting-edge technology is developed at Lund University in Sweden and based on a spectroscopic method that measures lung volume changes and oxygen gas concentration. Neola Medical is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to global health care. The company was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company’s Certified Adviser is FNCA Sweden AB.

Attachments
Neola Medical’s CEO highlights recent steps toward market approval in the Autumn 2024 Investor Letter
Neola Medical Investor Letter Autumn 2024

Datum 2024-10-01, kl 07:00
Källa MFN
Bifogade filer
Neola Medical’s CEO highlights recent steps toward market approval in the Autumn 2024 Investor Letter
Neola Medical Investor Letter Autumn 2024
Affiliate
Alla Aktier tipsar: Har du redan ett konto på Avanza? Varför inte skapa ett på Nordnet också och jämföra funktioner, courtage mm. Det tar inte lång tid, du fixar det direkt här med BankID
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet